GERN — Geron Corporation

Geron Corporation (GERN) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Q4 2025 Net Revenue: $48 million, consistent with expectations.
• Full Year 2025 Net Revenue: $184 million, significantly up from $76 million in 2024, marking Rytelo's first full commercial year.
• Total Operating Expenses (2025): Approximately $255 million, in line with guidance.
• Gross-to-Net Deductions: Increased to 17.7% from 14.5% year-over-year, attributed to wider 340B utilization and expanded GPO contracting.
• Cash Position: Approximately $400 million as of December 31, 2025, down from $503 million in 2024.
• 2026 Operating Expense Guidance: Projected between $230 million and $240 million, indicating a reduction at the midpoint.

2. Strategic Updates and Business Highlights:

• Geron is focusing on evolving into a commercially driven organization with a refined strategy for Rytelo, targeting second-line lower-risk MDS patients.
• Key initiatives include increasing awareness among healthcare professionals and expanding research partnerships to enhance real-world experience with Rytelo.
• Rytelo's commercial strategy emphasizes targeted engagement with high-volume community accounts and effective marketing channels, aiming for a 9% demand growth in Q4 2025.

3. Forward Guidance and Outlook:

• 2026 Rytelo Net Revenue Guidance: Expected to be between $220 million and $240 million, with growth anticipated to accelerate in the latter half of the year.
• The company aims to maintain operational execution and financial discipline while investing in commercial strategies and ISTs (Investigator-Sponsored Trials).

4. Bad News, Challenges, or Points of Concern:

• While there is optimism for growth, the company faces competitive pressures, particularly from ESAs (Erythropoiesis-Stimulating Agents) and the evolving treatment landscape with luspatercept.
• The need for careful navigation of European market entry and HTA (Health Technology Assessment) processes poses additional challenges.
• The increase in gross-to-net deductions may impact net revenue realization as the business matures.

5. Notable Q&A Insights:

• Management highlighted the importance of both breadth (new accounts) and depth (repeat prescriber engagement) in driving revenue growth.
• There is an estimated 8,000 second-line patients in the U.S. market for Rytelo, with a focus on converting more of these patients as treatment paradigms shift.
• The company sees a path to profitability but emphasizes that 2026 will prioritize strategic investments over immediate profitability.
• Management is cautious about European expansion due to potential pricing pressures and is assessing partnerships to navigate the market effectively.

Overall, Geron Corporation is positioned for growth in 2026, leveraging its strategic initiatives around Rytelo while being mindful of competitive and market challenges.